Schaak J, Schedl P, Shenk T
Howard Hughes Medical Institute, Department of Biology, Princeton University, NJ 08544.
Nucleic Acids Res. 1990 Mar 25;18(6):1499-508. doi: 10.1093/nar/18.6.1499.
The requirements for topoisomerases in transcription of adenovirus and HeLa cell genes were analyzed using drugs that specifically inhibit either topoisomerases I or II. Cleavage of viral DNA by topoisomerases in the presence of either camptothecin or VM26 was used to determine drug concentrations that led to maximal inhibition of ligation in the cleavage and ligation step of topoisomerase I or II respectively. Inhibition of topoisomerase II with VM26 did not cause a direct reduction in transcription of adenoviral genes or HeLa cell heat shock genes. VM26 did, however, interfere with other cellular processes. It reduced nucleoside uptake into HeLa cells from the medium, and it altered the normal nuclear to cytoplasmic ratio of specific RNAs. Treatment of cells with camptothecin to inhibit topoisomerase I reduced but did not abolish transcription of viral and HeLa cell genes. Transcription mediated by both RNA polymerases I and II was reduced. Topoisomerase II did not appear to substitute for topoisomerase I in transcription since treatment of cells with VM26 and camptothecin did not reduce transcript accumulation relative to cells treated with camptothecin alone.
使用特异性抑制拓扑异构酶I或II的药物,分析了腺病毒和HeLa细胞基因转录过程中对拓扑异构酶的需求。在喜树碱或VM26存在的情况下,通过拓扑异构酶对病毒DNA的切割,来确定分别导致拓扑异构酶I或II的切割和连接步骤中连接作用最大程度抑制的药物浓度。用VM26抑制拓扑异构酶II并没有直接降低腺病毒基因或HeLa细胞热休克基因的转录。然而,VM26确实干扰了其他细胞过程。它减少了核苷从培养基进入HeLa细胞的摄取,并改变了特定RNA正常的核质比。用喜树碱处理细胞以抑制拓扑异构酶I,减少但没有消除病毒和HeLa细胞基因的转录。RNA聚合酶I和II介导的转录均减少。由于用VM26和喜树碱处理细胞相对于仅用喜树碱处理的细胞并没有减少转录本积累,因此拓扑异构酶II在转录过程中似乎不能替代拓扑异构酶I。